Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.39 |
| ▸ | HTR5A | P47898 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036500 | 0.89 | HTR5A (0.48) | JAK2SLC9A1HTR5ATGFBR1GRM2 | |
| SCHEMBL30037152 | 0.88 | KMO (0.42) | JAK2PTPN11IDO1GABRA5MBNL1 | |
| SCHEMBL25551942 | 0.88 | KMO (0.42) | JAK2PTPN11IDO1GABRA5MBNL1 | |
| SCHEMBL25551949 | 0.84 | CTSA (0.39) | JAK2SLC9A1IDO1GABRA5 | |
| SCHEMBL30036962 | 0.84 | CTSA (0.39) | JAK2SLC9A1IDO1GABRA5 | |
| SCHEMBL30035813 | 0.80 | HTR5A (0.43) | JAK2SLC9A1HTR5AGRM2CDC7 | |
| SCHEMBL30036520 | 0.79 | MBNL1 (0.39) | PTPN11IDO1MBNL1CCNE2CCNE1 | |
| SCHEMBL25551944 | 0.79 | MBNL1 (0.39) | PTPN11IDO1MBNL1CCNE2CCNE1 | |
| SCHEMBL30037130 | 0.76 | MBNL1 (0.47) | HTR5AMBNL1 | |
| SCHEMBL25552003 | 0.76 | MBNL1 (0.47) | HTR5AMBNL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | JAK2 1113/4885SLC9A1 4614/4885HTR5A 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.